Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Randomized, Placebo-Controlled, Double-Blind Phase 3 Trial Comparing, Relative to Placebo, the Effect of Isoquercetin on Thromboembolic Events in Patients with Metastatic Pancreatic Cancer (CATIQ P3)

Next Previous
X
Search
Trial Profile

A Randomized, Placebo-Controlled, Double-Blind Phase 3 Trial Comparing, Relative to Placebo, the Effect of Isoquercetin on Thromboembolic Events in Patients with Metastatic Pancreatic Cancer (CATIQ P3)

Status: Planning
Phase of Trial: Phase III

Latest Information Update: 10 May 2021

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Isoquercetin (Primary)
  • Indications Pancreatic cancer; Venous thromboembolism
  • Focus Registrational; Therapeutic Use
  • Acronyms CATIQ P3
  • Sponsors Quercis Pharma

    • Most Recent Events

    • 04 May 2021 According to a Quercis Pharma media release, the company has entered into a Special Protocol Assessment (SPA) agreement with the U.S. Food and Drug Administration (FDA).Study start-up activities already under way, and the company looks forward to initiating this Phase 3 study.
    • 29 Jan 2021 New trial record
    • 25 Jan 2021 According to a Quercis Pharma AG media release, company will peruse U.S. Food and Drug Administration (FDA) approval for the prevention of VTE in all cancer types based on two Phase 3 studies.
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top